Alexandria Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $506K | Buy |
11,775
+394
| +3% | +$17.5K | 0.05% | 183 |
|
|
2021
Q2 | $446K | Sell |
11,381
-20
| -0.2% | -$778 | 0.04% | 193 |
|
|
2021
Q1 | $413K | Sell |
11,401
-722
| -6% | -$25.6K | 0.04% | 194 |
|
|
2020
Q4 | $446K | Buy |
12,123
+161
| +1% | +$5.91K | 0.05% | 185 |
|
|
2020
Q3 | $417K | Buy |
11,962
+1,902
| +19% | +$66.7K | 0.05% | 182 |
|
|
2020
Q2 | $312K | Buy |
10,060
+1,354
| +16% | +$46K | 0.04% | 193 |
|
|
2020
Q1 | $270K | Sell |
8,706
-759
| -8% | -$25.9K | 0.04% | 195 |
|
|
2019
Q4 | $352K | Sell |
9,465
-394
| -4% | -$14K | 0.05% | 199 |
|
|
2019
Q3 | $336K | Sell |
9,859
-3,983
| -29% | -$145K | 0.05% | 194 |
|
|
2019
Q2 | $568K | Sell |
13,842
-735
| -5% | -$29.2K | 0.08% | 174 |
|
|
2019
Q1 | $587K | Sell |
14,577
-106
| -0.7% | -$4.25K | 0.09% | 170 |
|
|
2018
Q4 | $608K | Buy |
14,683
+2,974
| +25% | +$123K | 0.1% | 160 |
|
|
2018
Q3 | $490K | Sell |
11,709
-158
| -1% | -$6.08K | 0.07% | 180 |
|
|
2018
Q2 | $408K | Sell |
11,867
-141
| -1% | -$4.82K | 0.06% | 184 |
|
|
2018
Q1 | $405K | Buy |
12,008
+626
| +5% | +$21.5K | 0.06% | 191 |
|
|
2017
Q4 | $391K | Buy |
11,382
+4,050
| +55% | +$138K | 0.06% | 194 |
|
|
2017
Q3 | $248K | Sell |
7,332
-113
| -2% | -$3.63K | 0.06% | 126 |
|
|
2017
Q2 | $237K | Sell |
7,445
-94
| -1% | -$2.96K | 0.06% | 129 |
|
|
2017
Q1 | $245K | Buy |
7,539
+258
| +4% | +$8.13K | 0.06% | 123 |
|
|
2016
Q4 | $224K | Sell |
7,281
-1,017
| -12% | -$31K | 0.06% | 128 |
|
|
2016
Q3 | $266K | Buy |
8,298
+4,618
| +125% | +$154K | 0.05% | 128 |
|
|
2016
Q2 | $123K | Sell |
3,680
-250
| -6% | -$7.98K | 0.02% | 171 |
|
|
2016
Q1 | $111K | Sell |
3,930
-1,968
| -33% | -$56.2K | 0.02% | 182 |
|
|
2015
Q4 | $181K | Buy |
5,898
+1,462
| +33% | +$46K | 0.05% | 146 |
|
|
2015
Q3 | $132K | Sell |
4,436
-431
| -9% | -$13.8K | 0.03% | 166 |
|
|
2015
Q2 | $155K | Sell |
4,867
-2,558
| -34% | -$83.4K | 0.03% | 155 |
|
|
2015
Q1 | $245K | Buy |
7,425
+2,757
| +59% | +$87.7K | 0.09% | 88 |
|
|
2014
Q4 | $138K | Buy |
4,668
+136
| +3% | +$3.9K | 0.05% | 123 |
|
|
2014
Q3 | $127K | Buy |
4,532
+318
| +8% | +$8.93K | 0.06% | 129 |
|
|
2014
Q2 | $119K | Sell |
4,214
-2,347
| -36% | -$66.9K | 0.05% | 133 |
|
|
2014
Q1 | $200K | Sell |
6,561
-1,425
| -18% | -$42.5K | 0.09% | 105 |
|
|
2013
Q4 | $232K | Sell |
7,986
-173
| -2% | -$5.04K | 0.1% | 95 |
|
|
2013
Q3 | $222K | Sell |
8,159
-9,205
| -53% | -$250K | 0.1% | 93 |
|
|
2013
Q2 | $461K | Buy |
+17,364
| New | +$480K | 0.23% | 61 |
|
Other funds holding PFE
Alexandria Capital's PFE Position: Q3 2021 in Review
Alexandria Capital increased its Pfizer (PFE) stake by 3.5% in Q3 2021, buying an estimated $17.5K and bringing the position to 11,775 shares worth $506K. The position accounts for 0.05% of the portfolio, ranked #183.
Alexandria Capital first reported a position in PFE in Q2 2013 and has held it in 34 quarters since. The position peaked at $608K in Q4 2018. 2,804 funds tracked by Wall St. Rank hold PFE as of Q3 2021.
- Alexandria Capital held 11,775 shares of Pfizer worth $506K as of Q3 2021.
- Alexandria Capital bought 394 Pfizer shares in Q3 2021, an estimated $17.5K.
- Pfizer made up 0.05% of Alexandria Capital's portfolio in Q3 2021, its #183 holding.
- Alexandria Capital first reported a position in Pfizer in Q2 2013 and has held it in 34 quarters since.
- Alexandria Capital's Pfizer position peaked at $608K in Q4 2018.
- 2,804 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.
Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.